UroGen Pharma (URGN) Assets Average (2018 - 2026)
UroGen Pharma's (URGN) quarterly Assets Average came in at $227.1 million in Q1 2026, down 14.85% YoY from $266.7 million in Q1 2025, and up 17.81% on a QoQ basis from $192.8 million in Q4 2025.
UroGen Pharma (URGN) Assets Average (2018 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 9 years of Assets Average data on file, last reported at $227.1 million in Q1 2026.
- Quarterly Assets Average fell 14.85% year-over-year to $227.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $227.1 million (down 14.85% YoY) and the FY2025 annual result came in at $243.1 million, up 4.77% from the prior year.
- Assets Average rose to $227.1 million in Q1 2026, from $192.8 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $293.8 million in Q4 2024 to a low of $104.2 million in Q2 2023.
- A 5-year average of $191.5 million and a median of $189.4 million in 2024 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2024 — Assets Average surged 131.58% — and 2025, when it sank 34.4%.
- Tracing URGN's Assets Average over 5 years: stood at $132.0 million in 2022, then soared by 40.84% to $186.0 million in 2023, then soared by 58.0% to $293.8 million in 2024, then slumped by 34.4% to $192.8 million in 2025, then rose by 17.81% to $227.1 million in 2026.
- The last three Assets Average figures came in at $227.1 million (Q1 2026), $192.8 million (Q4 2025), and $196.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn | 253.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 253.14 Mn |
| Mar 31, 2026 | 227.07 Mn |
| Dec 31, 2025 | 192.75 Mn |
| Sep 30, 2025 | 196.88 Mn |
| Jun 30, 2025 | 228.17 Mn |
| Mar 31, 2025 | 266.66 Mn |
| Dec 31, 2024 | 293.83 Mn |
| Sep 30, 2024 | 291.90 Mn |
| Jun 30, 2024 | 241.21 Mn |
| Mar 31, 2024 | 189.44 Mn |
| Dec 31, 2023 | 185.97 Mn |
| Sep 30, 2023 | 144.50 Mn |
| Jun 30, 2023 | 104.16 Mn |
| Mar 31, 2023 | 124.29 Mn |
| Dec 31, 2022 | 132.05 Mn |
| Sep 30, 2022 | 137.31 Mn |
| Jun 30, 2022 | 155.93 Mn |
| Mar 31, 2022 | 142.73 Mn |
| Dec 31, 2021 | 127.17 Mn |
| Sep 30, 2021 | 144.19 Mn |